When the GLP-1 agonists and DPP-4 inhibitors were first introduced, there were differences in the reports on whether patients with T2DM had lower GLP-1 levels compared to normal non-diabetic subjects [15–17]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.